3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
2
Sarcoma
1
Other hematologic neoplasm
1
CNS
1
Conditions
Skin Neoplasms
1
Multiple Sclerosis, Relapsing-Remitting
1
Multiple Sclerosis
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Carcinoma, Basal Cell
1
Interventions
Nivolumab
168
Ipilimumab
152
pembrolizumab
143
Cyclophosphamide
126
Interleukin-2
70
aldesleukin
69
fludarabine phosphate
68
Radiotherapy
67
Biopsy
53
Temozolomide
48
Blood Specimen Collection
45
Peripheral Blood Stem Cell Transplantation
44
fludarabine
43
Radiosurgery
40
trametinib
38
Vemurafenib
36
dabrafenib
33
sargramostim
32
Bevacizumab
31
Aminolevulinic Acid
31
Magnetic Resonance Spectroscopy
30
Mycophenolic Acid
29
Specimen Handling
28
Whole-Body Irradiation
27
Photochemotherapy
26
Imiquimod
26
CTLA-4 Antigen
26
Busulfan
26
Tacrolimus
25
Surveys and Questionnaires
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Dimethyl Fumarate
×
Dermatologic
×
Clear all
NCT06705608
2024-11-26
MS; FTY720
University of British Columbia
Completed
4,000 enrolled
NCT02546440
2023-03-31
DMF-CTCL
Universitätsmedizin Mannheim
Phase 2
Completed
25 enrolled